title: Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
abstract: Small cell lung cancer with interstitial lung disease (ILD-SCLC) is difficult to treat because of the risk of fatal pneumonitis. Our study aims to evaluate the validity of topotecan (TOP) as chemotherapy for patients with relapsed ILD-SCLC. Overall survival was compared between TOP and other drugs as second-line treatments for ILD-SCLC patients. Forty-seven patients began chemotherapy and second-line treatment was administered in 48.5% of relapsed cases. The response rate of TOP for second-line therapy was 16.7%. Hematologic toxicities were grade 4 anemia, grade 3 neutropenia and grade 3 thrombocytopenia. Mild pulmonary toxicity was observed in 1 case. Patients receiving TOP as second-line treatment showed no significant difference in survival when compared to patients who underwent other regimens (median survival time 179 vs. 76 days; p =0.76). TOP is a well tolerated drug and is a viable candidate for second-line treatment of ILD-SCLC patients.
authors.affiliation: Department of Thoracic Malignancy, Osaka Prefectural Medical Center For Respiratory And Allergic Diseases, Osaka, Japan. suzukih@ra.opho.jp
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: T
authors.initials: T
authors.lastname: Hirashima
authors.forename: M
authors.initials: M
authors.lastname: Kobayashi
authors.forename: S
authors.initials: S
authors.lastname: Sasada
authors.forename: N
authors.initials: N
authors.lastname: Okamoto
authors.forename: N
authors.initials: N
authors.lastname: Uehara
authors.forename: Y
authors.initials: Y
authors.lastname: Matsuura
authors.forename: M
authors.initials: M
authors.lastname: Tamiya
authors.forename: N
authors.initials: N
authors.lastname: Morishita
authors.forename: M
authors.initials: M
authors.lastname: Higashiguchi
authors.forename: T
authors.initials: T
authors.lastname: Tsumori
authors.forename: I
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000150:complications*; D008175:Lung Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000150:complications* / Q000188:drug therapy*; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan